SCT-OGP fusion protein expression and its potential role as osteoporosis therapy.
- Author:
Yu LIU
1
;
Xiao-Li YANG
;
Xiang HE
;
Ying-Fang PENG
;
Ping LI
;
Yan-Hong ZHANG
;
Qing-Jun MA
;
Hui ZHONG
Author Information
1. The General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Calcitonin;
genetics;
Calcium;
blood;
Histones;
genetics;
Intercellular Signaling Peptides and Proteins;
genetics;
Mice;
NIH 3T3 Cells;
Osteoblasts;
drug effects;
Osteoporosis;
drug therapy;
Rats;
Rats, Wistar;
Recombinant Fusion Proteins;
biosynthesis;
isolation & purification;
therapeutic use
- From:
Chinese Journal of Biotechnology
2006;22(4):539-544
- CountryChina
- Language:Chinese
-
Abstract:
Osteoporosis is a disease of bone metabolic disorder, the incidence of which increases sharply in old people. Calcitonin (CT) is a peptide hormone containing 32 amino acid that can inhibit osteoclasts activity. Osteogenic Growth Peptide (OGP) is a peptide hormone with 14 amino acid. It is an autocrine mitogen for osteoblastic and firbroblastic cells which has anabolic activiy. Six SCT and OGP DNA segments were chemically synthesized and ligated into a yeast expression vector pPIC9. The recombinant plasmid was transformed into pichia pastoris GS115. Finally, we got two stable SCT-OGP high expression clones after screening. Purifed protein can stimulate the proliferation of osteoblastic and fibroblastic cells, and also stimulate serum ALP activity and decrease serum calcium level using mice as animal models, demonstrating its potential role in oteoporosis therapy.
